These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 1455866)
1. [Cure of acute myeloblastic leukemia in a child with Down syndrome and tetralogy of Fallot]. Balcar-Boroń A; Nowaczyk-Michalak A; Graduszewska-Czerebiej K Wiad Lek; 1992 Mar; 45(5-6):220-3. PubMed ID: 1455866 [No Abstract] [Full Text] [Related]
3. Results of the Italian AIEOP/LAM 8204 study for the treatment of childhood AML: an update. Amadori S; Mandelli F; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Defazio D Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():114-5. PubMed ID: 2653484 [No Abstract] [Full Text] [Related]
4. Combination chemotherapy with DATV regimen in treatment of adult acute nonlymphocytic leukemia. Lou FD; Zhou Q; Liu HC; Meng FY; Wang YZ Chin Med J (Engl); 1993 Nov; 106(11):876-8. PubMed ID: 8143502 [No Abstract] [Full Text] [Related]
5. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia]. Sanz MA; Lorenzo JI; Sanz GF; Martín Aragonés G; Rafecas FJ; Martínez JA; Gomis F Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626 [No Abstract] [Full Text] [Related]
7. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Palle J; Frost BM; Petersson C; Hasle H; Hellebostad M; Kanerva J; Schmiegelow K; Lönnerholm G; Anticancer Drugs; 2009 Jan; 20(1):7-14. PubMed ID: 19342996 [TBL] [Abstract][Full Text] [Related]
8. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial. Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788 [TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of post-consolidation therapy in acute non-lymphoid leukaemia: a study of the Italian cooperative group GIMEMA. Petti MC; Mandelli F; Vegna ML; Broccia G; Carotenuto M; De Rosa F; Di Marco P; Di Raimondo F; Fioritoni G; Leone G Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():119-20. PubMed ID: 2653486 [No Abstract] [Full Text] [Related]
10. Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia. Nowrousian MR; Pfeiffer R; Schaefer UW; Osieka R; Niederle N; Anders C; Schmidt CG Haematol Blood Transfus; 1987; 30():352-5. PubMed ID: 3305206 [No Abstract] [Full Text] [Related]
11. [Diagnosis and intensive treatment of acute leukemia in pregnancy]. Sierra J; Urbano Ispizua A; Cararach V; Carreras E; Fortuny A; Grañena A; Rozman C Med Clin (Barc); 1987 Jan; 88(1):28-31. PubMed ID: 3469488 [No Abstract] [Full Text] [Related]
12. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia. Neri A; Comis M; Brugiatelli M; Martino B; Ronco F Haematologica; 1989; 74(1):113-4. PubMed ID: 2498174 [No Abstract] [Full Text] [Related]
13. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A; J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036 [TBL] [Abstract][Full Text] [Related]
14. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456 [TBL] [Abstract][Full Text] [Related]
15. Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia. Aul C; Heyll A Haematol Blood Transfus; 1987; 30():356-60. PubMed ID: 3476367 [No Abstract] [Full Text] [Related]
16. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807 [No Abstract] [Full Text] [Related]
18. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. Vogler WR; Velez-Garcia E; Omura G; Raney M Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581 [No Abstract] [Full Text] [Related]
19. [Short-term intensive consolidation chemotherapy in the treatment of acute non-lymphocytic leukemia]. Nagata K; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K Gan To Kagaku Ryoho; 1992 Jul; 19(7):1079-81. PubMed ID: 1626944 [No Abstract] [Full Text] [Related]
20. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia]. Paśnicki M Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239 [No Abstract] [Full Text] [Related] [Next] [New Search]